Started in 2020 by Dr. Saeed Darvish-Kazem and Dr. Sam Elfassy, KeyOps is a physician engagement platform that allows doctors to quickly share their expert opinions with healthcare stakeholders such as government institutions, hospitals, universities, and life science companies. KeyOps has seen exponential growth in 2021, as its members used it to share their experiences during the COVID-19 pandemic.
Based in Toronto, ON, it has grown to a team of 7 with hundreds of physician members across Canada. It has plans to expand its services to the United States in early 2022, coinciding with the release of its iOS and Android apps.
Based in Toronto, ON, it has grown to a team of 7 with hundreds of physician members across Canada. It has plans to expand its services to the United States in early 2022, coinciding with the release of its iOS and Android apps.
Employees: 11-50
Total raised: $4M
Founded date: 2018
Investors 3
| Date | Name | Website |
| - | Velocity F... | velocity.f... |
| 03.11.2023 | CIBC Innov... | innovation... |
| 10.11.2023 | Graphite V... | graphitevc... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 16.12.2022 | Seed | $4M | - |
Mentions in press and media 3
| Date | Title | Description |
| 27.06.2023 | CIBC Innovation Banking Provides Growth Capital to KeyOps | TORONTO–(BUSINESS WIRE)–June 27, 2023– CIBC Innovation Banking announced today that it has provided growth financing to KeyOps, a Toronto-based insights and engagement platform that connects physicians to life science companies. KeyOps will... |
| 13.12.2022 | KeyOps Raises $4M in Seed Funding | KeyOps, a Toronto, Canada-based Insights-as-a-Service (IaaS) startup, raised $4M in Seed funding. The round was led by Graphite Ventures, with participation from MaRS IAF, StarForge, Archangel Network fund, Velocity Fund, Carol Leaman, Jame... |
| - | KeyOps | “A revolutionary physician engagement platform that allows doctors to quickly share their expert opinions with healthcare stakeholders such as government institutions, hospitals, universities, and life science companies.” |